Shares of Biogen Idec (NASDAQ:BIIB) were initially flat when the company reported earnings last week but have seen a sell-off since then. The slump in the stock, however, was partially due to an overall downward trend in biotech at the moment, and in this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass note that they actually see a lot to like here.

Revenue for the company beat estimates by about 7% because of the upsides from both Tecfidera and Avonex, and although earnings per share did ultimately miss by $0.08 per share, David says he sees that as mostly an expectations game. The company mentioned doing $200 million in deals this year, but its deals with Eisai and Sangamo that fell early this year and totaled nearly $150 million meant that the $200 million figure didn't spread evenly throughout the year, and affected Wall Street's expectations.

In the video, David and Michael go over the numbers and Biogen's impressive pipeline, and tell investors why this sell-off may be a case of market overreaction.

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

David Williamson, Michael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.